IL2 and hereditary clear cell renal cell carcinoma: High-dose interleukin-2 (IL-2), a potent inducer of cytotoxic T-cells and NK cells, was one of the first FDA-approved immunotherapy drugs in advanced cancer, with a role in the treatment of melanoma and renal cell carcinoma [4].